Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions.
- Transaction Price: $41.78 per American Depositary Share (ADS).
- Transaction Type: Re-investment of dividends on unvested deferred annual bonus awards.
Material Changes
The filing reports an increase in the actual and notional interests of Mrs. D P Connelly, a Person Discharging Managerial Responsibility. The changes resulted from the re-investment of dividends paid on ADSs held in the unvested portion of the GSK 2009 Deferred Annual Bonus Plan Post-Tax awards and matching elements.
| Director/PDMR | Actual ADSs Acquired | Notional ADSs Acquired |
|---|---|---|
| Mrs D P Connelly | 51.56 | 51.64 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that vest following the end of the relevant measurement period.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Mrs. D P Connelly following this transaction.
- Confirm the vesting schedule and measurement period for the GSK 2009 Deferred Annual Bonus Plan.
- Check for any other concurrent filings regarding executive compensation or share ownership changes.